linkedin

Press Releases

Samsung BIO Insight

Unlocking the Possibilities to the Future of Biopharma | 2022 BIO International Convention

Unlocking the Possibilities to the Future of Biopharma


2022 BIO International Convention 

 

 

This year, the world’s largest biotech partnering event, BIO International Convention, was back in person for the first time since the COVID-19 pandemic. Samsung Biologics participated in the event from June 13-16 in San Diego, California, where it showcased its capabilities as a leading CDMO and actively met with potential clients for future projects. In line with the conference’s theme of “Limitless Together”, the event demonstrated a promising future of breakthrough innovations, paving the way for the next decade of biopharma.

 

 

1.png
2.png
3.png
4.png
5.png 

 

     

Looking Towards The Next Frontier


Since its foundation in 2011, Samsung Biologics has participated in BIO every year and even when the conference moved online during the COVID-19 outbreak. As the pandemic enters its endemic phase, the company and biotech industry are now looking to what’s next in the latest trends and research.

 

"We are very excited to participate in the first face-to-face BIO International Convention in three years since the pandemic and to introduce our latest and innovative CDMO capabilities to clients,” said John Rim, CEO and President of Samsung Biologics. "We are continuously evolving to offer services for CDO, mRNA, and multi-modal products to further secure the success drivers for sustainable growth. We are also at the forefront in the biopharma industry to address critical issues like climate change as we aim to provide sustainable and enduring value for people worldwide and contribute to making the world a healthier place for all.”  

  

 

6.png

7.png

 

 

Driven. For a Sustainable Life.


Samsung Biologics presented its commitment to sustainability at the ESG section of the booth and showcased the company’s promise to become a “Green CDMO.” The company launched its new sustainability branding video, “Driven. For Sustainable Life.”, to mark the promise of building a healthier and sustainable future for all. 

 

 

13.png


“With our aims to become a sustainable partner and a ‘Green CDMO’, we are actively investing in environment-conscious practices and technologies to mitigate the risks of climate change in the greater areas we impact,” said James Choi, EVP and Chief Information & Marketing Officer. “We are also working collaboratively on many global initiatives to help drive the net zero transition across the industry.”

 

 

8.png
9.png
  

Last year, Samsung Biologics joined together with leaders from global biopharma companies and public sector organizations including the WHO and Unicef, as part of the Sustainable Markets Initiative (SMI), convened by His Royal Highness The Prince of Wales, to accelerate the delivery of net zero and establish sustainable healthcare to improve individual, societal, and planetary health. 

 

“Samsung Biologics is also working at an industry-level to drive successful decarbonization,” Choi added. "We joined the Frontier 1.5D project to develop a climate risk management model, which affirms our commitment to shaping climate-resilient practices and policies across all value chains in the pharmaceutical and healthcare sectors.”

 

 

Addressing Key Insights into the Next Blockbuster


In addition to exhibition booths and networking receptions, over 100+ panel sessions covered various industry topics, such as next-generation biotherapeutics, mRNA, public policy, patient advocacy, and more. 

 

Pierre Catignol, Executive Vice President and Head of the Manufacturing Center, participated in a panel session to address key insights into mRNA and give guidance on what to look for in a CDMO partner.

 

During the session, Catignol introduced the unique capabilities of Samsung Biologics and how it offers fully integrated mRNA manufacturing services all at a single site in Songdo.

 

 

14.png

 

 

Limitless Together to Bring New Opportunities

 

19.png

 

“BIO International is a place where bio-industry professionals and experts can come together to explore ways to cooperate and create new opportunities. This year’s theme of ‘Limitless Together’ is to show the cross-boundary collaboration of bio officials and the unlimited challenges in unknown areas,” said Adela Wilson from BIO. “Samsung Biologics’ performance was remarkable, both with its creative booth design and outstanding service competitiveness.”

 

 

15.png
16.png
17.png
18.png

 

 

Samsung Biologics is at the forefront of building a sustainable future for all. By leveraging its world’s largest manufacturing capacity and continuous innovation, the company will strive to make innovative biologics accessible to all and create a healthier future. 

 

 

20.png

 

 

Driven. For Life.

 

 

Related Contents

BIO Insight The Power of One I Samsung Biologics’ mRNA Capabilities

Life @ Samsung Biologics Driven. For Climate Action

 

Unlocking the Possibilities to the Future of Biopharma


2022 BIO International Convention 

 

 

This year, the world’s largest biotech partnering event, BIO International Convention, was back in person for the first time since the COVID-19 pandemic. Samsung Biologics participated in the event from June 13-16 in San Diego, California, where it showcased its capabilities as a leading CDMO and actively met with potential clients for future projects. In line with the conference’s theme of “Limitless Together”, the event demonstrated a promising future of breakthrough innovations, paving the way for the next decade of biopharma.

 

 

1.png
2.png
3.png
4.png
5.png 

 

     

Looking Towards The Next Frontier


Since its foundation in 2011, Samsung Biologics has participated in BIO every year and even when the conference moved online during the COVID-19 outbreak. As the pandemic enters its endemic phase, the company and biotech industry are now looking to what’s next in the latest trends and research.

 

"We are very excited to participate in the first face-to-face BIO International Convention in three years since the pandemic and to introduce our latest and innovative CDMO capabilities to clients,” said John Rim, CEO and President of Samsung Biologics. "We are continuously evolving to offer services for CDO, mRNA, and multi-modal products to further secure the success drivers for sustainable growth. We are also at the forefront in the biopharma industry to address critical issues like climate change as we aim to provide sustainable and enduring value for people worldwide and contribute to making the world a healthier place for all.”  

  

 

6.png

7.png

 

 

Driven. For a Sustainable Life.


Samsung Biologics presented its commitment to sustainability at the ESG section of the booth and showcased the company’s promise to become a “Green CDMO.” The company launched its new sustainability branding video, “Driven. For Sustainable Life.”, to mark the promise of building a healthier and sustainable future for all. 

 

 

13.png


“With our aims to become a sustainable partner and a ‘Green CDMO’, we are actively investing in environment-conscious practices and technologies to mitigate the risks of climate change in the greater areas we impact,” said James Choi, EVP and Chief Information & Marketing Officer. “We are also working collaboratively on many global initiatives to help drive the net zero transition across the industry.”

 

 

8.png
9.png
  

Last year, Samsung Biologics joined together with leaders from global biopharma companies and public sector organizations including the WHO and Unicef, as part of the Sustainable Markets Initiative (SMI), convened by His Royal Highness The Prince of Wales, to accelerate the delivery of net zero and establish sustainable healthcare to improve individual, societal, and planetary health. 

 

“Samsung Biologics is also working at an industry-level to drive successful decarbonization,” Choi added. "We joined the Frontier 1.5D project to develop a climate risk management model, which affirms our commitment to shaping climate-resilient practices and policies across all value chains in the pharmaceutical and healthcare sectors.”

 

 

Addressing Key Insights into the Next Blockbuster


In addition to exhibition booths and networking receptions, over 100+ panel sessions covered various industry topics, such as next-generation biotherapeutics, mRNA, public policy, patient advocacy, and more. 

 

Pierre Catignol, Executive Vice President and Head of the Manufacturing Center, participated in a panel session to address key insights into mRNA and give guidance on what to look for in a CDMO partner.

 

During the session, Catignol introduced the unique capabilities of Samsung Biologics and how it offers fully integrated mRNA manufacturing services all at a single site in Songdo.

 

 

14.png

 

 

Limitless Together to Bring New Opportunities

 

19.png

 

“BIO International is a place where bio-industry professionals and experts can come together to explore ways to cooperate and create new opportunities. This year’s theme of ‘Limitless Together’ is to show the cross-boundary collaboration of bio officials and the unlimited challenges in unknown areas,” said Adela Wilson from BIO. “Samsung Biologics’ performance was remarkable, both with its creative booth design and outstanding service competitiveness.”

 

 

15.png
16.png
17.png
18.png

 

 

Samsung Biologics is at the forefront of building a sustainable future for all. By leveraging its world’s largest manufacturing capacity and continuous innovation, the company will strive to make innovative biologics accessible to all and create a healthier future. 

 

 

20.png

 

 

Driven. For Life.

 

 

Related Contents

BIO Insight The Power of One I Samsung Biologics’ mRNA Capabilities

Life @ Samsung Biologics Driven. For Climate Action

 

SITE MAP

close
Close

Thank you for Subscribing to Our Newsletter

아래 다운로드 버튼을 클릭하시면 바로 다운로드 하실 수 있습니다.

Close

Subscribe to Our Newsletter

파일 다운로드를 위해 뉴스레터 구독용 이메일 주소를 입력해주세요.
* 구독자라면 구독중인 이메일 주소를 입력해주세요.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

뉴스레터 구독 서비스를 등록하시면 당사 뉴스룸에서 제공되는
삼성바이오로직스의 최신 소식과 관심 분야별 유용한 정보를 받아 보실 수 있습니다.

Subscribe to Our Newsletter
    • - 개인정보 수집 목적 : 이메일 발신서비스 제공
    • - 개인정보 수집 항목 : 이메일 주소, 회사명, 이름, 직급, 국가
    • - 이용 및 보관 기간 : 이메일 발신서비스 해지 시까지

    개인정보 수집에 동의하지 않을 시, 뉴스레터 서비스를 이용할 수 없습니다.

    삼성바이오로직스 개인정보 보호정책에 따라 개인정보는 안전하게 관리됩니다.

close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION

Copyright Samsung Biologics. All rights reserved